ZAP70 Antibody (2F3.2) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-47774PCP
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
CyTOF-ready, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Simple Western
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Monoclonal Mouse IgG2a Kappa Clone # 2F3.2
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for ZAP70 Antibody (2F3.2) [PerCP]
Immunogen
Recombinant ZAP-70 protein including residues 1-254 and encompassing SH2 domains of human ZAP70 (Uniprot: P43403)
Localization
Cell Surface and Cytoplasmic
Specificity
ZAP70 is a 70kDa protein tyrosine kinase found in T-cells and natural killer cells. Control of this protein translation is via the IgVH gene. In Western blotting of whole cell lysates of normal peripheral blood mononuclear cells, the antibody labels a band corresponding to ZAP70. In Western blotting of whole cell lysates of CD19-positive Purified leukemia cells from patients with Ig-unmutated and Ig-mutated CLL, the antibody labels a band corresponding to ZAP70 in the Ig-unmutated CLL samples, whereas no band is observed in the Ig-mutated CLL samples. In Western blotting of cell lysates of Jurkat cells (T-lymphoblastic cell line), the antibody labels a band of 70kDa protein. In Western blotting of cell lysates of A431 cells (carcinoma cell line), no band is observed. ZAP70 protein is expressed in leukemic cells of approximately 25% of chronic lymphocytic leukemia (CLL) cases as well. Anti-ZAP70 expression is an excellent surrogate marker for the distinction between the Ig-mutated (anti-ZAP70 negative) and Ig-unmutated (anti-ZAP70 positive) CLL subtypes and can identify patient groups with divergent clinical courses. The anti-ZAP70 positive Ig-unmutated CLL cases have been shown to have a poorer prognosis.
Marker
Chronic Lymphocytic Leukemia Marker
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2a Kappa
Description
This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Applications for ZAP70 Antibody (2F3.2) [PerCP]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Simple Western
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: ZAP70
Long Name
Zeta-chain [TCR] Associated Protein Kinase 70 kDa
Alternate Names
mrtle, mur, SRK, STD, TZK
Gene Symbol
ZAP70
Additional ZAP70 Products
Product Documents for ZAP70 Antibody (2F3.2) [PerCP]
Product Specific Notices for ZAP70 Antibody (2F3.2) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...